Kathleen A. Hilliard

Author

Case Western Reserve University

Also Known As

K A Hilliard, K Hilliard, K.A. Hilliard, Katherine Hilliard, Kathleen A. Hilliard, Kathleen Hilliard

Publications

Citations

H-Index

Concepts

All Affiliations

Case Western Reserve University Rainbow Babies & Children's Hospital University of Washington University of Iowa Emory University

About

Kathleen A. Hilliard is an author at Case Western Reserve University specializing in medicine, pulmonary fibrosis, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.4K
2	Biomedical Engineering	2	2	36
3	Engineering	1	1	14
4	Biomolecular Engineering	1	1	14
5	Cellular Therapies	1	1	22

Kathleen A. Hilliard

Publications

Citations

H-Index

Page 1

	Year	Citations
Inflammatory cytokines in cystic fibrosis lungs. Tracey L. Bonfield, James R. Panuska, Michael W. Konstan, American Journal of Respiratory and Critical Care Medicine InflammationInflammatory CytokinesFibrosisInflammatory Lung DiseaseLung Inflammation	1995	704
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Michael W. Konstan, Kathleen A. Hilliard, Tonya M. Norvell, American Journal of Respiratory and Critical Care Medicine AsthmaInflammatory Lung DiseaseLung InflammationImmunologyPediatric Lung Disease	1994	515
Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution Michael W. Konstan, Pamela B. Davis, Jeffrey S. Wagener, Human Gene Therapy	2004	295
Leukotriene B <sub>4</sub> Markedly Elevated in the Epithelial Lining Fluid of Patients with Cystic Fibrosis Michael W. Konstan, Ronald W. Walenga, Kathleen A. Hilliard, American Review of Respiratory Disease	1993	152
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis Michael W. Konstan, Gerd Döring, Sonya L. Heltshe, Journal of Cystic Fibrosis Ltb4 Receptor AntagonistInflammatory Lung DiseaseAdvanced Lung DiseasePediatricsPediatric Lung Disease	2014	133
Effect of Ibuprofen on Neutrophil Migration in Vivo in Cystic Fibrosis and Healthy Subjects Michael W. Konstan, Jeanne E. Krenicky, Marcie Finney, Journal of Pharmacology and Experimental Therapeutics	2003	82
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis** Richard C. Ahrens, T. A. Standaert, Janice L. Launspach, Pediatric Pulmonology	2002	58
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis* Nael A. McCarty, T. A. Standaert, M. Teresi, Pediatric Pulmonology	2002	47
A phase I study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic fibrosis Erica A. Roesch, Tracey L. Bonfield, Hillard M. Lazarus, Journal of Cystic Fibrosis Regenerative MedicineCell TherapyTransplantationMedicineStem Cell Transplantation	2022	22
Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution Michael W. Konstan, Pamela B. Davis, Jeffrey S. Wagener, Human Gene Therapy NanoparticlesNanomedicineNasal MucosaDna NanotechnologyEngineering	2004	14

Page 1